TELA Bio Statistics
Total Valuation
TELA Bio has a market cap or net worth of $114.15 million. The enterprise value is $117.41 million.
| Market Cap | 114.15M |
| Enterprise Value | 117.41M |
Important Dates
The next estimated earnings date is Wednesday, August 7, 2024, after market close.
| Earnings Date | Aug 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TELA Bio has 24.66 million shares outstanding. The number of shares has increased by 28.11% in one year.
| Shares Outstanding | 24.66M |
| Shares Change (YoY) | +28.11% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 1.74% |
| Owned by Institutions (%) | 74.46% |
| Float | 16.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.81 |
| Forward PS | 1.40 |
| PB Ratio | 7.94 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.13, with a Debt / Equity ratio of 2.83.
| Current Ratio | 4.13 |
| Quick Ratio | 3.12 |
| Debt / Equity | 2.83 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.59 |
Financial Efficiency
Return on equity (ROE) is -155.30% and return on invested capital (ROIC) is -82.16%.
| Return on Equity (ROE) | -155.30% |
| Return on Assets (ROA) | -48.60% |
| Return on Capital (ROIC) | -82.16% |
| Revenue Per Employee | $278,181 |
| Profits Per Employee | -$177,524 |
| Employee Count | 227 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 1.37 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.52% in the last 52 weeks. The beta is 1.02, so TELA Bio's price volatility has been similar to the market average.
| Beta (5Y) | 1.02 |
| 52-Week Price Change | -54.52% |
| 50-Day Moving Average | 5.30 |
| 200-Day Moving Average | 5.77 |
| Relative Strength Index (RSI) | 44.34 |
| Average Volume (20 Days) | 408,485 |
Short Selling Information
The latest short interest is 955,980, so 3.88% of the outstanding shares have been sold short.
| Short Interest | 955,980 |
| Short Previous Month | 929,136 |
| Short % of Shares Out | 3.88% |
| Short % of Float | 5.85% |
| Short Ratio (days to cover) | 4.00 |
Income Statement
In the last 12 months, TELA Bio had revenue of $63.15 million and -$40.30 million in losses. Loss per share was -$1.67.
| Revenue | 63.15M |
| Gross Profit | 43.55M |
| Operating Income | -45.23M |
| Pretax Income | -40.30M |
| Net Income | -40.30M |
| EBITDA | -34.16M |
| EBIT | -34.99M |
| Loss Per Share | -$1.67 |
Balance Sheet
The company has $37.41 million in cash and $40.67 million in debt, giving a net cash position of -$3.26 million or -$0.13 per share.
| Cash & Cash Equivalents | 37.41M |
| Total Debt | 40.67M |
| Net Cash | -3.26M |
| Net Cash Per Share | -$0.13 |
| Equity (Book Value) | 14.38M |
| Book Value Per Share | 0.58 |
| Working Capital | 47.44M |
Cash Flow
In the last 12 months, operating cash flow was -$43.67 million and capital expenditures -$788,000, giving a free cash flow of -$44.46 million.
| Operating Cash Flow | -43.67M |
| Capital Expenditures | -788,000 |
| Free Cash Flow | -44.46M |
| FCF Per Share | -$1.81 |
Margins
Gross margin is 68.97%, with operating and profit margins of -71.62% and -63.82%.
| Gross Margin | 68.97% |
| Operating Margin | -71.62% |
| Pretax Margin | -63.82% |
| Profit Margin | -63.82% |
| EBITDA Margin | -54.10% |
| EBIT Margin | -55.41% |
| FCF Margin | -70.40% |
Dividends & Yields
TELA Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.11% |
| Shareholder Yield | -28.11% |
| Earnings Yield | -35.30% |
| FCF Yield | -38.94% |
Analyst Forecast
The average price target for TELA Bio is $13.00, which is 180.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.00 |
| Price Target Difference | 180.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 28.89% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TELA Bio has an Altman Z-Score of -5.11 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.11 |
| Piotroski F-Score | 3 |